Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12968212 | 0.90 | DRD2 (0.41) | TP53ALOX15LTA4HALDH1A1HTT | |
| SCHEMBL11949128 | 0.87 | LTA4H (0.41) | ELANETP53MAPTLTA4HHPGD | |
| SCHEMBL20148280 | 0.87 | PLA2G2A (0.47) | TP53ALOX15LTA4HALDH1A1HTT | |
| SCHEMBL14489702 | 0.85 | ELANE (0.49) | ELANETP53ALOX15LTA4HPTGS1 | |
| SCHEMBL9123683 | 0.85 | ELANE (0.49) | ELANETP53ALOX15MAPTLTA4H | |
| SCHEMBL13144454 | 0.83 | NQO1 (0.42) | TP53MAPTLTA4HHPGDALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9119760 | 0.83 | ELANE (0.47) | ELANETP53ALOX15MAPTLTA4H | |
| SCHEMBL17547160 | 0.82 | TP53 (0.47) | TP53ALOX15MAPTHPGDALDH1A1 | |
| SCHEMBL13429872 | 0.78 | MAPT (0.36) | ELANETP53MAPTLTA4HHPGD | |
| SCHEMBL18704569 | 0.78 | MAPT (0.47) | ELANEMAPTLTA4HHPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9318706-B2 | Laminated structure, method for producing same, and electronic element comprising same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | EPCAM, ITGA1, ITGB1 | ELANE 942/4885TP53 3701/4885ALOX15 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.